

Sonoma Pharmaceuticals, Inc.

May 2023



Legal Disclaimers

INVESTOR PRESENTATION

This communication is for informational purposes only. The information contained herein does not purport to be all-inclusive. The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any information contained herein. Any data on past performance is no indication as to future performance. Sonoma Pharmaceuticals, Inc. and its subsidiaries (“Sonoma” or, the “Company”) assumes no obligation to update the information in this communication. This presentation is not an offer to buy or the solicitation of an offer to sell Sonoma securities.

FORWARD-LOOKING STATEMENTS

Except for historical information herein, matters set forth in this presentation are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries.

These forward-looking statements are identified by the use of words such as “believe,” “achieve,” and “expect,” among others. Forward-looking statements in this presentation are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, the Company will not have sufficient capital to implement its business plan, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

TRADEMARKS AND INTELLECTUAL PROPERTY

All trademarks, service marks, and trade names of the Company and its subsidiaries or affiliates used herein are trademarks, service marks, or registered trademarks of the Company as noted herein. Any other product, company names, or logos mentioned herein are the trademarks and/or intellectual property of their respective owners.





About Sonoma

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, wound care, eye care, nasal care, oral care, podiatry, animal health and non-toxic disinfectants. Sonoma's products are clinically-proven to reduce infections, itch, pain, scarring, and harmful inflammatory responses safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma's stabilized HOCl kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated, assisting the body in its natural healing process. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners.



Investor Highlights

Diverse global healthcare leader

- Focused on billion-dollar markets in Rx and OTC dermatology, wound care, eye, oral and nasal care, podiatry, animal health and non-toxic disinfectants, treating common injuries, infections and irritations
- Over **20 years of experience** with over **100 clinical studies** and continual product innovation
- 21 U.S. FDA clearances as 510(k) medical devices, CE marks for over 39 products, and extensive worldwide regulatory clearances means products can be commercialized faster
- Robust and diverse international partner network selling into over **55 countries**
- Pharmaceutical-grade manufacturing capabilities in Mexico lowers COGS and creates opportunities for volume plays

Unique, patented and FDA-cleared, CE and ISO approved Microcyn® Technology

- HOCl is known to be among the safest and most effective ways to relieve itch, inflammation, redness and irritation while stimulating natural healing through increased oxygenation and eliminating persistent microorganisms and biofilms
- Microcyn effectively treats common everyday irritations, such as rashes, and chronic conditions, such as diabetic foot ulcers, making it a flexible treatment appealing to everyone. Unlike other common treatments such as steroids or antibiotics, Microcyn can be used long-term with no reported serious adverse effects and no contraindications. Microcyn is extremely safe and all-natural.
- Proven antipruritic, antimicrobial, antiviral and anti-inflammatory properties
- Non-toxic disinfectant approved in the U.S. and Australia for use against COVID-19

Growth Strategy

Expand distribution

- Expand Rx and OTC reach in U.S. in the dermatology, wound care, eye, oral and nasal care, podiatry, animal care and non-toxic disinfectants markets via direct-to-consumer sales and distribution partnerships
- Increase sales of dermatology products through the direct dispense model that generates Sonoma's highest margins by leveraging Sonoma's existing relationships with dermatologists and skin care professionals
- Increase direct-to-consumer marketing in niche markets to generate greater overall margins, while continuing to grow successful distribution partner network
- Expand non-toxic disinfectant sales; have recently secured EPA clearance in the U.S. and expect to commence sales in summer 2023

Invest in R&D to expand commercialization opportunities

- Introduce new technology to new markets by leveraging expertise of existing distribution partnerships
- Fully commercialize robust pipeline of new products via direct-to-consumer sales or distribution partnerships, and seek additional regulatory clearances for new indications and in high-value markets; currently pursuing new 510(k) clearances for facial dermatology and oral rinse indications

Continue to introduce new high margin products

Manufacturing capabilities can support significant future growth, leading to improved margins overall

Robust International Distribution Network

Established and growing distribution network with **OVER 40 GLOBAL PARTNERS** generating strong revenues internationally and in the U.S.

- Expand presence in new markets by replicating what works in existing markets
- Continue to add new distribution partners and grow existing relationships
- Continue co-development of innovative new products with partners in the U.S. and internationally
- Work with partners to seek new approvals and certifications



Recent Business Developments

Continuously expanding our distributor network

- Entered into a distribution agreement with **Daewoong Pharmaceutical Co., Ltd.**, one of the largest pharmaceutical companies in South Korea, in January 2023 for the marketing and distribution of Primocyn™ Skin Solution products
- Sonoma's Microcyn® Rx products, including wound care, prescription dermatology products Celacyn® and Levicyn®, and prescription eye care Acuicyn®, received a Distribution and Pricing Agreement (DAPA) in January 2023 for distribution by the Defense Logistics Agency (DLA), enabling our partner, **EMC Pharma, LLC** to enter into distribution agreements for these products with federal customers
- In April 2023, our partner **Te Arai BioFarma Limited** launched BabySoothe for diaper rash applications in Taiwan
- Our partner **Microderm Technologies** recently launched Dermodacyn for wound care applications in Thailand
- Signed a new partner, **TPVN Pharmaceuticals Company Limited**, for distribution of Endocyn Root Canal Irrigation Solution in Vietnam
- Our partner **Brill Pharma SL** is now selling Sonoma's eye care products in Italy, Spain and Portugal and plans to sell in Germany and France next year
- Our MicrocynAH® products are now available through Pets at Home, with 453 stores across the UK, through our partner **Manna Pro Products, LLC**

Recent Business Developments

Expanding commercialization opportunities by investing in R&D

- In March 2023, Sonoma announced new EPA claims for its **Nanocyn® Hospital-Grade Disinfectant** for effective use against **MRSA, Salmonella, Norovirus, Poliovirus**, and as a **fungicide**. Nanocyn was previously approved for use against **COVID-19** as well as emerging pathogens including **Ebola virus, Mpox**, and **SARS-CoV-2**. Nanocyn also received the esteemed **Green Seal® Certification** after surpassing a series of rigorous standards that measure environmental health, sustainability and product performance.

Introduction of new products using our Microcyn® technology

- On April 11, 2023, Sonoma launched **Podiacyn™ Advanced Everyday Foot Care** direct to consumers for over-the-counter use in the United States.
- On January 4, 2023, Sonoma launched a line of office dispense products exclusively for skin care professionals, including two new products, **Reliefacyn® Plus Itch-Burn-Rash-Pain Relief Hydrogel** and **Rejuvacyn® Plus Skin Repair Cooling Mist**. Along with **Regenacyn® Plus Scar Management Hydrogel**, these office dispense products are targeted to dermatology practices and medical spas.

New Market Opportunities

Sonoma is expanding its partnerships and product offerings in the all-natural skin care and medical spa industries.

- The global **natural skin care** products market size was valued at \$6.7 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.6% from 2022 to 2030.¹
- The global **medical spa** market size was valued at \$16.4 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 14.97% from 2023 to 2030.²
 - North America dominated the medical spa market with a share of 41.5% in 2022, attributable in part to increasing demand for minimally invasive aesthetic procedures.³

Sonoma also continues to expand its presence in the global **animal health** market that was valued at \$39.9 billion in 2021 and is expected to witness a compound annual growth rate (CAGR) of 10.0% from 2022 to 2030.⁴

1. Grand View Research, *Natural Skin Care Products Market Report, 2022-2030*, available at <https://www.grandviewresearch.com/industry-analysis/natural-skin-care-products-market>

2. Grand View Research, *Medical Spa Market Size, Share & Growth Analysis Report 2030*, available at <https://www.grandviewresearch.com/industry-analysis/medical-spa-market>

3. *Ibid.*

4. Grand View Research, *Animal Health Market Size & Share Report, 2022-2030*, available at <https://www.grandviewresearch.com/industry-analysis/animal-health-market>

Sonoma's Microcyn® Technology

Microcyn®
Technology

Stable triple-action topical technology

- A powerful anti-microbial – reduces microbial load, including destruction of biofilms
- Anti-inflammatory agent – reduces itch and pain
- Anti-pruritic activity
- Tissue healing (increased blood/oxygen flow to wound)

Unparalleled safety – No drug-to-drug interaction or contraindications


- Millions of patients treated worldwide without single report of serious adverse effect
- 30+ human clinical trials with over 1,500 patients
- Over 100 clinical papers available on our website

No mutations or resistance

- Overused antibiotics may cause deadly epidemics such as MRSA


Cost effective

- Preventative – reduces hospital/physician visits
- Medicare/hospital savings – faster healing reduces hospital stays



What is Hypochlorous Acid?

HOCl generation within the neutrophil




During the activation of neutrophils, respiratory bursts generate hydrogen peroxide (H_2O_2) and the activated granule enzyme myeloperoxidase converts H_2O_2 to [hypochlorous acid \(HOCl\)](#)



- Produced by neutrophils in the body as part of its defense mechanism
- Highly active against bacterial, viral, and fungal pathogens
- Shown to rapidly kill spore-forming and non-spore forming bacteria and have significant activity against biofilms

Phagocytosis & Oxidative burst



Over 100 research articles and case and clinical studies showcasing both the efficacy and safety of our Microcyn® technology

Received: 26 June 2019 | Revised: 25 November 2019 | Accepted: 10 December 2019
DOI: 10.1111/jocd.13280

REVIEW ARTICLE



Topical stabilized hypochlorous acid: The future gold standard for wound care and scar management in dermatologic and plastic surgery procedures

Michael H. Gold MD, FAAD^{1,2,3,4} | Anneke Andriessen PhD⁵ | Ashish C. Bhatia MD, FAAD^{6,7} | Patrick Bitter Jr MD, FAAD⁸ | Suneel Chilukuri MD, FAAD, FACMS^{9,10} | Joel L. Cohen MD, FAAD, FACMS^{11,12} | Chris W. Robb MD, PhD¹³

¹Gold Skin Care Center, Nashville, TN, USA
²Tennessee Clinical Research Center, Nashville, TN, USA
³Vanderbilt University School of Nursing, Nashville, TN, USA
⁴School of Medicine, Meharry Medical College, Nashville, TN, USA
⁵Andriessen Consultants & Radboud UMC, Nijmegen, The Netherlands
⁶Northwestern University - Feinberg School of Medicine, Chicago, IL, USA
⁷Q&A Dermatology, Itasca, IL, USA
⁸Advanced Aesthetic Dermatology, Los Gatos, CA, USA
⁹Refresh Dermatology, Houston, TX, USA
¹⁰Baylor College of Medicine, Houston, TX, USA
¹¹AboutSkin Dermatology and DermSurgery, Greenwood Village and Lone Tree, CO, USA
¹²University of California Irvine Department of Dermatology, Irvine, CA, USA
¹³Skin and Allergy Center, Spring Hill, TN, USA

Correspondence
Anneke Andriessen, Zwenkgras 25, 6581 RK Malden, The Netherlands.
Email: anneke.a@tiscali.nl

Funding information
IntraDerm Pharmaceuticals, Grant/Award Number: The literature research for this review was sponsor

Abstract

Background: Hypochlorous acid (HOCl), a naturally occurring molecule produced by the immune system, is highly active against bacterial, viral, and fungal microorganisms. Moreover, HOCl is active against biofilm and increases oxygenation of the wound site to improve healing. Natural HOCl is unstable; through technology, it can be stabilized into an effective topical antiseptic agent.

Aim: This paper focuses on the use of topical stabilized HOCl in wound and scar management for pre-, peri-, and postprocedures—including its ability to reduce the occurrence hypertrophic scars and keloids. The role of the product in other skin conditions is beyond the scope of this article.


Methods: A panel comprising clinicians with experience in cosmetic and surgical procedures met late 2018 to discuss literature search results and their own current clinical experience regarding topical stabilized HOCl. The panel of key opinion leaders in dermatology and plastic surgery defined key insights and consensus statements on the direction of use for the product.

Results: Topical stabilized HOCl provides an optimal wound healing environment and, when combined with silicone, may be ideal for reducing scarring. Additionally, in contrast to chlorhexidine, HOCl, used as an antiseptic skin preparation, raises no concerns of ocular- or ototoxicity.

Conclusions: For wound care and scar management, topical stabilized HOCl conveys powerful microbicidal and antibiofilm properties, in addition to potency as a topical wound healing agent. It may offer physicians an alternative to other less desirable wound care measures.

KEYWORDS

hypertrophic scars, keloid scars, scar management, stabilized hypochlorous acid, wound care



Download : [Download high-res image \(577KB\)](#)

Download : [Download full-size image](#)

Figure 1. Stability of severe acute respiratory syndrome SARS-CoV. (a) Stability of SARS-CoV-2 in dried form. (b) Stability of SARS-CoV-2 in solution. (c) Stability of SARS-CoV in dried form. (d) Stability of SARS-CoV in solution. Legend: Blue line, 4°C; orange line, 20–25°C; grey line, 30°C.

COVER FOCUS

Optimizing Wound Healing for Cosmetic and Medical Dermatologic Procedures

Among the options for wound management is hypochlorous acid, a broad-action antimicrobial and anti-inflammatory agent.

BY ASHISH BHATIA, MD; JEFFREY HSU, MD; TODD SCHLESINGER, MD; AND ROBERT W.

Multiple factors influence wound healing. However, three primary conditions are essential for optimal wound healing with minimal risk of scarring. First, optimal wound healing requires the eradication of pathogenic bacteria and biofilm. Second, optimal wound healing requires an excellent blood supply and proper oxygenation. Finally, the proper immunological healing factors must be present in order for the wound to heal. With these optimal healing “primers” in place, the outcome is minimal scarring, rapid healing, and good structure and function of the healed wound site.

Physicians who perform aesthetic procedures, especially energy-based treatments or injections, are particularly focused on rapid healing, minimum pain, minimum down time, and optimal appearance. A controlled wound, as created with these tools and technologies, is associated with improved healing compared to uncontrolled or traumatic wounds. Nevertheless, proper wound care serves to further support healing for optimal cosmesis. Consider that, in some cases, aesthetic physicians are creating controlled wounds with the intention to revise existing scars, and the need to support wound healing becomes evident.

For dermatologists, wound care generally is focused on post-surgical management for biopsy and excision sites or post-procedural skincare following energy-based procedures or peels. At-home skin prep for excisions or Mohs micrographic surgery is not common. However, many patients interested in aesthetic procedures are advised to implement a skincare routine in advance of the procedure. In the aesthetic patient, retinoids and related compounds, botanical ingredients, growth factors, and antioxidants may be recommended individually or in combination, depending on the patient, the procedure, and the physician preference.

Increasingly, evidence suggests that the care immediately before a surgery or procedure and the healing phase can have important effects on outcomes. For years, dermatologists have relied on conventional options for peri-procedural skincare: antiseptics to cleanse the skin immediately before a procedure, petrolatum ointments immediately after a procedure, and topical antibiotic ointments to reduce the risk of emerging infection and experience suggests that these may not be ideal.

The antiseptic preparations most commonly used in surgery in the US are iodopovidone and chlorhexidine. Iodopovidone dyes the clothing and the hair, and associated irritation are noxious for some patients. Chlorhexidine can be toxic to tissues, especially in the eye. Therefore, procedural dermatologists have grown concerned about its use. However, chlorhexidine has practical benefits over betadine, and, at least has been an important option. Chlorhexidine preparations—perhaps up to 72 hours—of antimicrobial can endure being washed with blood or fluids.

Use of topical antibiotic preparations for wound management is increasingly unpopular, due to concerns about development of bacterial resistance. Furthermore, topical antibiotics confer no activity against yeasts that reside on the skin and may infect wounds. Additionally, some topical formulations are associated with risks for allergic dermatitis. The associated inflammation in the wound is detrimental to wound healing and may contribute to redness, hyperpigmentation, or hypopigmentation. Alternative approaches to wound management and prevention have been emerging. The use of rich plasma (PRP), which is increasingly being ad-

Accepted: 13 February 2020
DOI: 10.1111/jocd.13230

REVIEW ARTICLE



Hypochlorous acid gel technology—Its impact on postprocedure treatment and scar prevention

Michael H. Gold MD, FAAD^{1,2,3,4} | Anneke Andriessen PhD⁵ | Steven H. Dayan MD⁶ | Sabrina G. Fabi MD⁷ | Z. Paul Lorenc MD, FACS^{8,9} | Meagan-Helen Henderson Berg MDCM¹⁰

¹Gold Skin Care Center, Nashville, TN, USA
²Tennessee Clinical Research Center, Nashville, TN, USA
³Vanderbilt University School of Nursing, Nashville, TN, USA
⁴School of Medicine, Meharry Medical College, Nashville, TN, USA
⁵Andriessen Consultants & Radboud UMC, Nijmegen, The Netherlands
⁶Department of Otolaryngology, Division of Facial Plastic and Reconstructive Surgery, University of Illinois, Chicago, IL, USA
⁷Cosmetic Laser Dermatology, San Diego, CA, USA
⁸Lorenc Aesthetic Plastic Surgery Center, New York, NY, USA
⁹Department of Plastic Surgery, Lenox Hill Hospital, New York, NY, USA
¹⁰Faculty of Medicine, McGill University, Montreal, Canada

Correspondence
Dr Anneke Andriessen, Zwenkgras 25, 6581 RK Malden, The Netherlands.
Email: anneke.a@tiscali.nl

Funding information
IntraDerm Pharmaceuticals, Grant/Award Number: supported literature research with an educational grant

Summary

Background: A pre- and postprocedure regime aimed at prevention of infection, reduction of inflammation and risk of scarring, is to enable optimal outcomes.

Objectives: The role of a hypochlorous acid containing spray and translucent scar gel formulation that combines modified silicon oil with hypochlorous acid, was explored for pre- and postprocedure treatment and scar management.

Methods: For this purpose a literature review was conducted to explore the value of the technology used in pre- and postprocedural regimes. A panel of dermatologists and plastic surgeons who practice in the United States discussed the summarized search results, taking into account their current clinical practice. A nominal group process for consensus was used, followed by online reviews of the manuscript.

Results: Based on panel discussions, consensus was reached regarding clinical recommendations given for postprocedure treatment and scar management. The hypochlorous acid products are produced with electrolysis and are classified among biocidal substances. The technology has demonstrated efficacy and safety for pre- and postprocedure use. The safety of hypochlorous solution use demonstrated to be comparable to that of standard local antiseptics. Small studies demonstrated better results with the scar gel compared to silicone gel regarding the appearance of hypertrophic and keloid scars, relief of associated pruritus and pain.

Conclusions: A postprocedure regime using this technology, aimed at preventing infection, reducing inflammation, and promoting healing is proposed to have benefits over current regimes as it appears to be effective, safe, and well tolerated.

KEYWORDS

hypochlorous acid technology, postprocedure care, scar management

1 | INTRODUCTION

Clinical concerns over pre- and postprocedure care and scar management are at the forefront. They are balancing antiseptic properties and cytotoxicity with severity of colonization to assure a proper healing environment and enhance outcomes. Our immune system

naturally produces a compound called hypochlorous acid (HOCl) to eradicate bacteria and other invading pathogens within the body. This compound has also shown antipruritic and anti-inflammatory effects.^{1,2} A HOCl containing spray or super-oxidized solution for cleansing, irrigation, and disinfection of surgical sites (Alevyn Derm Spray) may decrease the risk of infection and optimize surgical

Diverse Product Portfolio

United States

Levicyn

Antimicrobial
Dermal Spray



Epicyn

Antimicrobial
Facial Cleanser



Celacyn

Scar Management
Gel



Regenacyn

Scar Gel



Microcyn Rx

Skin & Wound Care



Acucyn

Antimicrobial Eyelid
& Eyelash Hygiene



Nanocyn

Hospital Grade Disinfectant



Reliefacyn

Itch, Burn, Rash & Pain Care



Rejuvacyn

Skin Repair



Microcyn OTC

Wound & Skin Cleanser



Ocucyn

Eyelid & Eyelash Cleanser



Podiacyn

Everyday Foot Care



Pediacyc

Skin Care & First Aid for Children



U.S. Animal Health Care

MicrocynAH[®] family of advanced animal healthcare products, safe to use on pets and livestock, and perfect for hot spots, pink eye, scratches, skin rashes and ulcers, cuts, burns, post-surgical sites, irritated skin and lacerations.

- Sold in national pet-store retail chains and specialty stores such as **Petsmart**, **Chewy.com**, **Tractor Supply**, **Cabela's** and **Bass Pro Shops**. Distributed by



MicrocynVS[®] veterinarian-strength animal care for use in vet clinics and animal hospitals.



U.S. office dispense products exclusively for skin care professionals



- Generates highest margins for Sonoma
- Focused marketing to med spas and dermatology offices, which can resell products to their clients for a substantial margin

Direct-to-consumer products available through Shopify, Amazon and Amazon EU



U.S. Products



Epicyn
Keloid or Hypertrophic scars



Pediacyn
Atopic Dermatitis



Sinudox
Nasal care

EU Products



Microdacyn60
Oral care



Ocudox
Eye care



Mucoclyns
HOCl
Disinfectant

EU Products

Solutions that work naturally **for everybody**

Mucoclyns®
Decontamination solution



Exposure to germs and pathogens

Microdacyn60®
Oral Care



Mouth and throat infections

Sinudox®
Nasal care



Blocked nose or sinuses

Ocudox®
Eye lid solution



Blepharitis treatment

Epicyn®
Dermatology



Keloid or hypertrophic scar

Gramaderm®
Dermatology



Acne treatment

Pediacyn®
Dermatology



Atopic Dermatitis

Microdacyn60®
Wound Care



MicrocynAH® Animal Health Care



Middle East

Microdacyn Wound Care



Microsafe

Face Cool, Anti-Microbial, Baby Cool, Foot Cool, Lady Cool



Microsafe Disinfectant & Sanitizer



Latin America

Celacyn
Scar Management Gel



Gramacyn
Kit for Acne Skin



Australia and New Zealand

Microdacyn
Surgical Irrigation and
Wound Treatment



Epicyn
Treat Scars Right
from the Start



Microdox
Super-Oxidised Solution
Bladder & Catheter Rinse



Asia

Singapore, Malaysia, Thailand, Indonesia

Wound Care



China

Microcyn



Hong Kong

Microdacyn60 Oral Care



South Korea

BioDerm

Biodacyn60 Wound Care



The Philippines

Microdacyn



MicrocynAH



CUTTING EDGE MANUFACTURING



Currently operating at 30% capacity, with margin of approximately 35%

Flexible operations capable of high/small volume, large/small batch, private label, multiple configurations/packaging

- 57,153 square foot state-of-the-art facility
- ISO 9001, ISO 13485 and cGMP certified
- MOH, KFDA, SFDA, KSA, TGA, EN, Biocide and numerous other national listings and approvals
- Shipping to over 55 countries
- Highly trained staff of 153 employees




Manufacturing Facility



Located in Guadalajara, Mexico



Laboratory




Materials Testing Laboratory



Water Treatment System



Product



Air Systems



Packaging Area



Labeling



Boxing



Ready for shipment



Warehouse

THANK YOU

Sonoma Pharmaceuticals Inc.

5445 Conestoga Court, Suite 150 Boulder, CO 80301

United States of America

Phone: 1-(800) 759.9305

Email: busdev@sonomapharma.com

Website: www.sonomapharma.com



NASDAQ: SNOA

